Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × OTHER × Chalazion × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Unknown 2 Completed 2 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 304 Neoplasms 193 Prostatic Neoplasms 178 Carcinoma, Non-Small-Cell Lung 140 Lung Neoplasms 113 Pancreatic Neoplasms 103 Colorectal Neoplasms 99 Leukemia, Myeloid, Acute 85 Carcinoma, Hepatocellular 84 Neoplasm Metastasis 83 Multiple Myeloma 81 Brain Neoplasms 79 Lymphoma 77 Head and Neck Neoplasms 72 Melanoma 65 Leukemia 65 Ovarian Neoplasms 63 Glioblastoma 61 Leukemia, Lymphocytic, Chronic, B-Cell 60 Colonic Neoplasms 58 Precursor Cell Lymphoblastic Leukemia-Lymphoma 56 Recurrence 48 Lymphoma, Non-Hodgkin 48 Rectal Neoplasms 47 Lymphoma, Follicular 45 Hematologic Neoplasms 45 Squamous Cell Carcinoma of Head and Neck 43 Glioma 43 Lymphoma, Large B-Cell, Diffuse 42 Carcinoma, Renal Cell 38

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01763437 2017-01-12

TET

The Cleveland Clinic

Phase EARLY_PHASE1 Withdrawn

Meibomian Gland Dysfunction, Rosacea, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡